Evidence map›Paper›PMID 32816585›Full record

ArticleHealth security

The Emerging Neurobioeconomy: Implications for National Security.

Joseph DeFranco, Maureen Rhemann, James Giordano

Abstract read
In one paragraph

Article in Health security. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Joseph DeFrancoJoseph DeFranco, MS, is a Graduate Fellow, Program in Biodefense, Schar School of Policy and Government, George Mason University, Arlington, VA. Maureen Rhemann, PhD, is a Visiting Scholar, O'Neill-Pellegrino Program in Brain Science, Global Law and Policy, Georgetown University, Washington, DC. James Giordano, PhD, MPhil, is Professor, Departments of Neurology and Biochemistry, and Chief, Neuroethics Studies Program, Georgetown University Medical Center, Washington, DC; and a Senior Fellow, Project in Biosecurity, Technology, and Ethics, US Naval War College, Newport, RI.
Maureen RhemannJoseph DeFranco, MS, is a Graduate Fellow, Program in Biodefense, Schar School of Policy and Government, George Mason University, Arlington, VA. Maureen Rhemann, PhD, is a Visiting Scholar, O'Neill-Pellegrino Program in Brain Science, Global Law and Policy, Georgetown University, Washington, DC. James Giordano, PhD, MPhil, is Professor, Departments of Neurology and Biochemistry, and Chief, Neuroethics Studies Program, Georgetown University Medical Center, Washington, DC; and a Senior Fellow, Project in Biosecurity, Technology, and Ethics, US Naval War College, Newport, RI.
James GiordanoJoseph DeFranco, MS, is a Graduate Fellow, Program in Biodefense, Schar School of Policy and Government, George Mason University, Arlington, VA. Maureen Rhemann, PhD, is a Visiting Scholar, O'Neill-Pellegrino Program in Brain Science, Global Law and Policy, Georgetown University, Washington, DC. James Giordano, PhD, MPhil, is Professor, Departments of Neurology and Biochemistry, and Chief, Neuroethics Studies Program, Georgetown University Medical Center, Washington, DC; and a Senior Fellow, Project in Biosecurity, Technology, and Ethics, US Naval War College, Newport, RI.

Funding

Maternal Morbidity and Mortality: Risk Factors, Early Detection and Personalized InterventionUL1TR001409 · NCATS · GEORGETOWN UNIVERSITY · PI GONDRE-LEWIS, MARJORIE C, MELLMAN, THOMAS A · 2015 to 2024
$37.8M
NCATS NIH HHS UL1 TR001409
6 · The paper itself

Abstract

Neuroscience and neurotechnology (neuroS/T) are techniques and tools used to assess or affect the nervous system. Current and near-future developments are enabling an expanding palette of capabilities to understand and influence brain functions that can foster wellbeing and economic growth. This "neurobioeconomy" is rapidly growing, attributable in large part to the global dissemination of knowledge that fosters and contributes to scientific innovation, invention, and commercialization. As a result, several countries have initiated programs in brain research and innovation. Not all brain sciences engender security concerns, but a predominance in global biomedical, bioengineering, wellness/lifestyle, and defense markets enables considerable power. Such power can be leveraged in nonkinetic or kinetic domains, and several countries have identified neuroS/T as viable and of growing value for use in warfare, intelligence, and national security operations. In addition to the current focus on biotechnology, the United States and its allies must acknowledge the significance of brain science and its projected impact on the economy, national security, and lifestyles. In this article, we examine growth of the neuroS/T market, discuss how the neurobioeconomy poses distinct ethical and security issues for the broader bioeconomy, provide examples of such issues that arise from specific nation-state activity and technological commercialization, and propose a risk assessment and mitigation approach that can be engaged by the economic, scientific, and security communities.

Indexed as

Security MeasuresBiotechnologyEconomic DevelopmentInventionsNeurosciencesUnited StatesBioeconomyBioethicsBiotechnologyDual-use scienceNeuroscience

Identifiers

PMID32816585
PMCPMC7482132

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.